KYVERNA THERAPEUTICS, INC.

News Kyverna Therapeutics, Inc.

Equities

KYTX

US5019761049

Market Closed - Nasdaq Other stock markets 01:30:00 18/05/2024 am IST			5-day change	1st Jan Change
15.41 ^USD	+1.03%		+10.05%	0.00%

14/05	Kyverna Therapeutics Q1 Loss Narrows	MT
25/04	Nasdaq's revenue beats on strong demand for fintech products	RE

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kyverna Therapeutics Q1 Loss Narrows	15/05	MT
Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results	15/05	PR
Nasdaq's revenue beats on strong demand for fintech products	25/04	RE
First-in-Disease Use of Kyverna Therapeutics KYV-101 in Patients with Progressive Multiple sclerosis Published in Med1	01/04	AQ
First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med	30/03	PR
Kyverna Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03	CI
Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results	27/03	PR
Kyverna Therapeutics, Inc.(NasdaqGS:KYTX) added to S&P TMI Index	18/03	CI
Sector Update: Health Care Stocks Steady Pre-Bell Friday	08/03	MT
Kyverna Therapeutics Teams Up With Stanford University to Evaluate Investigational Multiple Sclerosis Drug	08/03	MT
Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis	08/03	PR
Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis	08/03	CI
JPMorgan Initiates Kyverna Therapeutics With Overweight Rating	04/03	MT
Morgan Stanley Starts Kyverna Therapeutics With Overweight Rating	04/03	MT
Kyverna Therapeutics Closes $366.9 Million Initial Public Offering	13/02	MT
Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares	13/02	PR
Moderna, Bayer-backed Metagenomi stock drops 32% on Nasdaq debut	10/02	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Stock Market
Equities
KYTX Stock
News Kyverna Therapeutics, Inc.

-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.

BENEFIT NOW